Since rare disease research gained traction in the 1980s, pharmaceutical investment in orphan drugs has accelerated. Orphan drugs have represented 50% or more of new molecular entities approved by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback